PR Newswire: news distribution, targeting and monitoring
Home Page > News Releases > APAC > Venus Medtech Acquires U.S. Company InterValve to Create a Systematic TAVR Treatment and Strengthen Global Expansion

Venus Medtech Acquires U.S. Company InterValve to Create a Systematic TAVR Treatment and Strengthen Global Expansion

2017-06-14 22:21
Share with Twitter

HANGZHOU, China, June 14, 2017 /PRNewswire/ -- Venus Medtech announced on June 13, 2017 that it has purchased U.S. Company InterValve, the supplier of balloon aortic valvuloplasty products, and that the relevant delivery procedures have been completed recently.

InterValve is a company focusing on transcatheter aortic valve treatment. The company's two trademark products, V8 and TAV8, are the world's pioneering aortic valvuloplasty balloon catheters with anatomical shapes. The unique 8-shaped design of the product, aiming at the lesion of aortic stenosis, can complete the percutaneous balloon angioplasty, the pre-dilatation and the post dilatation during the procdure of Transcather Aortic Valve Replacement(TAVR), compared with the traditional long cylindrical balloon, InterValve's balloon is more in line with the anatomical structure of the aortic valve, which can fully protect the valve annulus structure while maximizing the expansion of the valve. This type of 8-shaped balloon can bring the patients maximum safety and valve expansion.

InterValve Company's two aortic valvuloplasty balloon catheters V8 and TAV8 were approved by the U.S. FDA and have obtained the European CE mark in 2013. Sustaining a stable market sale in the United States and Europe, the two balloons have gained the recognition from the majority of European and American doctors. The acquisition of InterValve by Venus Medtech means not only the improvement and supplement of InterValve' s product line, but also the deepening and practicing of the global expansion of Venus Medtech. Starting from June 2017, Venus Medtech will be responsible for the global production and sales of V8 and TAV8.

Eric Zi, CEO of Venus Medtech, commented: "The balloon of Intervalve can accurately match the annulus and guarantee the steady expansion of the balloon, so the valve can fully expand itself without injuring the implanted valve. The fine match of the balloon with the valve's anatomical structure, combined with the use of the self-expanding transcatheter aortic valve, will greatly decrease the incidence rate of perivalvular leakage. It will also reduce the use of rapid pacemaker and significantly lower the risk of annulus tearing."

The cross-industry cooperation among research and development enterprises, medical institutions and financial investment provides a beneficial guarantee for the realization of Venus Medtech's innovation-driven development. Venus Medtech's VenusA-Valve has been approved by China Food and Drug Administration (CFDA) in April 2017, marking the first-ever CFDA approved TAVR device in the world. In addition to the success in the Chinese market, Venus Medtech has started its global expansion.

April 2016

Venus Medtech acquired German company Transcatheter Technologies.

September 2016 

Venus Medtech reached a strategic cooperation agreement with the U.S. Colibri Company. VenusP-valve pulmonary valve also launched its European CE clinical trial.

October 2016

A new generation of aortic valve replacement product with pre-loaded technology, Venibri, successfully completed the first human application in the world.

February 2017

Venus Medtech reached a strategic cooperation agreement with Keystone Heart, the supplier of thrombus protection devices.

June 2017

Venus Medtech purchased U.S. Company InterValve, the supplier of balloon aortic valvuloplasty products.

Venus Medtech focuses on not only the development and innovation of transcatheter aortic valve products, but also the total solution of TAVR, and has become the only supplier to provide the holistic treatment of "thrombus protection - balloon - valve" in the global TAVR field. Based on the characteristics of TAVR, the holistic treatment features a systematic and comprehensive reduction of the risk of brain and annulus injury that might be caused by TAVR, and guarantees a most comprehensive and complete solution for the patient. The differentiated products, dedicated to the pursuit of excellence, treatment effects and patient safety, will strengthen and consolidate the global leadership of Venus Medtech in the treatment of structural heart disease.

Source: Venus Medtech (Hangzhou) Inc.

Featured Video

Banking/Financial Service Recent Releases

Health Care/Hospital Recent Releases

Medical Equipment Recent Releases

Advanced Search
Search
  
  1. Products & Services
  2. News Releases
  3. Knowledge Center
  4. For Journalists & Media
  5. Multimedia Theater
  6. Contact Us